title: Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.
authors.affiliation: Université François Rabelais de Tours, Tours, France; Service de Dermatologie, CHU de Tours, France. Electronic address: machet@univ-tours.fr.
authors.forename: Laurent
authors.initials: L
authors.lastname: Machet
authors.forename: Mahtab
authors.initials: M
authors.lastname: Samimi
authors.forename: Maïa
authors.initials: M
authors.lastname: Delage
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.forename: Annabel
authors.initials: A
authors.lastname: Maruani
mesh_terms: D020083:Acquired Hyperostosis Syndrome / Q000175:diagnosis / Q000453:epidemiology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000453:epidemiology; D015897:Comorbidity; D003424:Crohn Disease / Q000175:diagnosis / Q000453:epidemiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D017497:Hidradenitis Suppurativa / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000453:epidemiology*; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000175:diagnosis / Q000453:epidemiology; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000453:epidemiology; D018570:Risk Assessment; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab